PRAX
Company Description
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 8.55M | 2.45M | 0 | 0 | 0 | 0 | 0 |
| Net Income | (303.27M) | (182.82M) | (123.28M) | (214.03M) | (167.06M) | (61.82M) | (35.51M) | (26.54M) |
| EPS | -13.48 | -10.21 | -18.69 | -69.33 | -58.96 | -103.61 | -348.24 | -306.73 |
| Free Cash Flow | (249.12M) | (131.76M) | (111.19M) | (185.49M) | (125.60M) | (52.62M) | (32.89M) | (20.78M) |
| FCF / Share | -11.07 | -7.36 | -16.86 | -60.36 | -44.38 | -88.19 | -322.53 | -240.25 |
| Operating CF | (249.07M) | (131.76M) | (111.14M) | (185.04M) | (124.55M) | (52.62M) | (32.79M) | (20.72M) |
| Total Assets | 937.91M | 483.11M | 87.95M | 115.13M | 292.75M | 303.18M | 47.69M | 19.83M |
| Total Debt | 110,000 | 1.37M | 2.50M | 3.50M | 4.31M | 763,000 | 1.46M | 0 |
| Cash & Equiv | 357.33M | 215.37M | 81.30M | 61.62M | 138.70M | 296.61M | 44.81M | 17.95M |
| Book Value | 878.14M | 445.45M | 69.67M | 76.11M | 250.81M | 287.46M | 40.11M | 14.68M |
| Return on Equity | -0.35 | -0.41 | -1.77 | -2.81 | -0.67 | -0.22 | -0.89 | -1.81 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 7.46M | 302,000 | 357,000 | 431,000 | 515,000 | 468,000 | 781,000 |
| Net Income | (92.56M) | (88.91M) | (73.93M) | (71.13M) | (69.30M) | (58.68M) | (51.91M) | (32.68M) | (39.55M) | (26.88M) | (24.63M) | (34.31M) |
| EPS | -3.20 | -3.52 | -3.36 | -3.31 | -3.29 | -2.94 | -2.75 | -1.74 | -2.84 | -2.97 | -2.72 | -7.38 |
| Free Cash Flow | (86.11M) | (77.26M) | (64.74M) | (54.80M) | (52.71M) | (56.12M) | (27.50M) | (27.28M) | (20.59M) | (23.65M) | (22.96M) | (30.96M) |
| FCF / Share | -2.98 | -3.43 | -2.95 | -2.55 | -2.50 | -2.81 | -1.46 | -1.45 | -1.48 | -2.61 | -2.54 | -6.66 |
| Operating CF | (86.05M) | (77.26M) | (64.74M) | (54.68M) | (52.71M) | (56.12M) | (27.50M) | (27.28M) | (20.59M) | (23.60M) | (22.96M) | (30.96M) |
| Total Assets | 1.46B | 937.91M | 396.39M | 452.83M | 478.74M | 483.11M | 416.26M | 441.06M | 250.41M | 87.95M | 106.72M | 133.50M |
| Total Debt | 1.44M | 110,000 | 436,000 | 755,000 | 1.07M | 1.37M | 1.66M | 1.95M | 2.22M | 2.50M | 2.76M | 3.01M |
| Cash & Equiv | 536.33M | 357.33M | 149.53M | 157.41M | 165.57M | 215.37M | 168.65M | 145.14M | 151.98M | 81.30M | 101.08M | 124.30M |
| Book Value | 1.41B | 878.14M | 343.50M | 404.22M | 439.21M | 445.45M | 382.67M | 419.10M | 229.68M | 69.67M | 86.76M | 105.62M |
| Return on Equity | -0.07 | -0.10 | -0.22 | -0.18 | -0.16 | -0.13 | -0.14 | -0.08 | -0.17 | -0.39 | -0.28 | -0.32 |
